These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8943690)

  • 1. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.
    Dirix LY; Tonnesen F; Cassidy J; Epelbaum R; ten Bokkel Huinink WW; Pavlidis N; Sorio R; Gamucci T; Wolff I; Te Velde A; Lan J; Verweij J
    Eur J Cancer; 1996 Oct; 32A(11):2019-22. PubMed ID: 8943690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG).
    Aamdal S; Lund B; Koier I; Houten M; Wanders J; Verweij J
    Cancer Chemother Pharmacol; 2000; 45(1):85-8. PubMed ID: 10647507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent. EORTC Early Clinical Trials Group.
    Verweij J; Aamdal S; Schellens J; Koier I; Lund B
    Oncol Res; 1994; 6(10-11):519-23. PubMed ID: 7620220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG).
    Pavlidis N; Hanauske AR; Gamucci T; Smyth J; Lehnert M; te Velde A; Lan J; Verweij J
    Ann Oncol; 1996 Jul; 7(5):529-31. PubMed ID: 8839911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
    Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
    Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
    J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. EORTC Early Clinical Trials Group.
    McLeod HL; Graham MA; Aamdal S; Setanoians A; Groot Y; Lund B
    Eur J Cancer; 1996 Aug; 32A(9):1518-22. PubMed ID: 8911111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of EO9 anti-tumour activity by hydralazine.
    Bibby MC; Sleigh NR; Loadman PM; Double JA
    Eur J Cancer; 1993; 29A(7):1033-5. PubMed ID: 8499134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
    Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR
    Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo.
    Collard J; Matthew AM; Double JA; Bibby MC
    Br J Cancer; 1995 Jun; 71(6):1199-203. PubMed ID: 7779711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia.
    Robertson N; Haigh A; Adams GE; Stratford IJ
    Eur J Cancer; 1994; 30A(7):1013-9. PubMed ID: 7946565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas.
    Walton MI; Bibby MC; Double JA; Plumb JA; Workman P
    Eur J Cancer; 1992; 28A(10):1597-600. PubMed ID: 1389472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
    Plumb JA; Workman P
    Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9.
    Smitskamp-Wilms E; Hendriks HR; Peters GJ
    Gen Pharmacol; 1996 Apr; 27(3):421-9. PubMed ID: 8723519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM; Phillips RM; Lim LE; Bibby MC
    Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.
    Choudry GA; Stewart PA; Double JA; Krul MR; Naylor B; Flannigan GM; Shah TK; Brown JE; Phillips RM
    Br J Cancer; 2001 Oct; 85(8):1137-46. PubMed ID: 11710826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model.
    Baas P; Michielsen C; Oppelaar H; van Zandwijk N; Stewart FA
    Int J Cancer; 1994 Mar; 56(6):880-5. PubMed ID: 8119776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioreductive agents: a clinical update.
    Boyer MJ
    Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of diaziquone in gastric and pancreatic cancers. A Southeastern Cancer Study Group Trial.
    DeSimone P; Kramer B; Omura GA; Bartolucci AA
    Am J Clin Oncol; 1986 Oct; 9(5):401-2. PubMed ID: 3776902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.
    Moore M; Maroun J; Robert F; Natale R; Neidhart J; Dallaire B; Sisk R; Gyves J
    Invest New Drugs; 1993 Feb; 11(1):61-5. PubMed ID: 8349438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.